Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Breast Neoplasms 15Leukemia 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Chronic-Phase 10Recurrence 8Prostatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Neoplasm Metastasis 6Leukemia, Lymphocytic, Chronic, B-Cell 6Melanoma 5Burkitt Lymphoma 5Pancreatic Neoplasms 4Leukemia, Myeloid, Acute 4Glioblastoma 4Blast Crisis 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neoplasms 3Lymphoma 3Gliosarcoma 3Sarcoma 2Salivary Gland Neoplasms 2Rhabdomyosarcoma 2Rectal Neoplasms 2Polycythemia Vera 2Oligodendroglioma 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Multiple Indications Cancer × Dasatinib × Clear all
NCT02297139 2023-05-06

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Bristol-Myers Squibb

Phase 2 Completed
17 enrolled 12 charts

Multiple Indications Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡